Landis Mark W, Pawlyk Basil S, Li Tiansen, Sicinski Piotr, Hinds Philip W
Molecular Oncology Research Institute and Department of Radiation Oncology, Tufts-New England Medical Center, 750 Washington Street #5609, Boston, Massachusetts 02111, USA.
Cancer Cell. 2006 Jan;9(1):13-22. doi: 10.1016/j.ccr.2005.12.019.
Cyclin D1 is a multifunctional protein that activates CDK4 and CDK6, titrates Cip/Kip CDK inhibitors to increase CDK2 activity, and modulates the function of certain transcription factors. To specifically test the importance of cyclin D1-associated kinase activity, we generated "knockin" mice expressing mutant cyclin D1 deficient in activating CDK4/6. The development of several cyclin D1-dependent compartments, including mammary glands, proceeds relatively normally in these animals, demonstrating that cyclin D1-associated kinase activity is largely dispensable for development of these tissues. Strikingly, knockin mice were resistant to breast cancers initiated by ErbB-2. These results demonstrate a differential requirement for cyclin D1-CDK4/6 kinase activity in development versus tumorigenesis and strongly support cyclin D1-dependent kinase activity as a specific therapeutic target in breast cancer.
细胞周期蛋白D1是一种多功能蛋白,它可激活细胞周期蛋白依赖性激酶4(CDK4)和细胞周期蛋白依赖性激酶6(CDK6),调节Cip/Kip CDK抑制剂以增加CDK2活性,并调节某些转录因子的功能。为了特异性测试与细胞周期蛋白D1相关的激酶活性的重要性,我们构建了表达缺乏激活CDK4/6能力的突变型细胞周期蛋白D1的“敲入”小鼠。包括乳腺在内的几个依赖细胞周期蛋白D1的组织区室在这些动物中发育相对正常,这表明与细胞周期蛋白D1相关的激酶活性在这些组织的发育中基本上是可有可无的。引人注目的是,敲入小鼠对由ErbB-2引发的乳腺癌具有抗性。这些结果表明,在发育与肿瘤发生过程中,对细胞周期蛋白D1-CDK4/6激酶活性的需求存在差异,并有力地支持了细胞周期蛋白D1依赖性激酶活性作为乳腺癌的一个特定治疗靶点。